Vaxcyte, Inc.
PCVX
$30.68
-$1.62-5.00%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -1.90% | 14.37% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 25.13% | 11.48% | |||
| Operating Income | -25.13% | -11.48% | |||
| Income Before Tax | -18.37% | -2.65% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -18.37% | -2.65% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -18.37% | -2.65% | |||
| EBIT | -25.13% | -11.48% | |||
| EBITDA | -25.59% | -11.63% | |||
| EPS Basic | -18.08% | -2.28% | |||
| Normalized Basic EPS | -18.07% | -2.32% | |||
| EPS Diluted | -18.08% | -2.28% | |||
| Normalized Diluted EPS | -18.07% | -2.32% | |||
| Average Basic Shares Outstanding | 0.25% | 0.36% | |||
| Average Diluted Shares Outstanding | 0.25% | 0.36% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||